Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 20

PMID 39302589

Authors

Rishi Rikhi

Michael D Shapiro

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The present review aims to summarize current evidence, explore underlying mechanisms, and help guide clinicians regarding statin therapy and diabetes risk in primary prevention.

Recent Findings: The observational and genetic epidemiology, as well as evidence from randomized controlled trials and meta-analyses, illustrate a modest, dose-dependent increase in risk of diabetes from statin therapy. Risk of new onset diabetes from statins appears to be greatest in those near the diagnostic threshold for diabetes or with diabetes risk factors prior to statin initiation. The risk of incident diabetes is vastly offset by the cardiovascular protection offered from statin therapy and should not deter guideline recommended statin initiation in primary prevention.

Citing Articles

Diabetes Risks of Statin Therapy-Coenzyme Q10 May Help.

Han X, Liu J, Gu Y, Li Y, Zhang W, Lv N Rev Cardiovasc Med. 2025; 26(2):26437.

PMID: 40026529 PMC: 11868890. DOI: 10.31083/RCM26437.

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Reiss A, Vasalani S, Albert J, Drewes W, Li K, Srivastava A Medicina (Kaunas). 2024; 60(11).

PMID: 39596912 PMC: 11596556. DOI: 10.3390/medicina60111727.

References

Ference B, Robinson J, Brook R, Catapano A, Chapman M, Neff D . Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016; 375(22):2144-2153. DOI: 10.1056/NEJMoa1604304. View

Ko M, Jo A, Kim Y, Kang S, Cho S, Jo S . Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. J Am Heart Assoc. 2019; 8(8):e011320. PMC: 6507181. DOI: 10.1161/JAHA.118.011320. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Mortensen M, Nordestgaard B . Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. JAMA Cardiol. 2019; 4(11):1131-1138. PMC: 6777225. DOI: 10.1001/jamacardio.2019.3665. View

Andersson T, Natman J, Mourtzinis G, Bager J, Bengtsson Bostrom K, Franzen S . The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes. Eur J Prev Cardiol. 2023; 30(17):1883-1894. DOI: 10.1093/eurjpc/zwad212. View

Culver A, Ockene I, Balasubramanian R, Olendzki B, Sepavich D, Wactawski-Wende J . Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012; 172(2):144-52. DOI: 10.1001/archinternmed.2011.625. View

Andersson N, Corn G, Dohlmann T, Melbye M, Wohlfahrt J, Lund M . LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals. J Am Coll Cardiol. 2023; 82(14):1381-1391. DOI: 10.1016/j.jacc.2023.07.027. View

Sattar N, McMurray J, Boren J, Rawshani A, Omerovic E, Berg N . Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. Circulation. 2023; 147(25):1872-1886. DOI: 10.1161/CIRCULATIONAHA.122.063374. View

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

10.

. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024; 12(5):306-319. PMC: 7615958. DOI: 10.1016/S2213-8587(24)00040-8. View

11.

Ward N, Watts G, Eckel R . Statin Toxicity. Circ Res. 2019; 124(2):328-350. DOI: 10.1161/CIRCRESAHA.118.312782. View

12.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

13.

Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-64. DOI: 10.1001/jama.2011.860. View

14.

Freeman D, Norrie J, Sattar N, Neely R, Cobbe S, Ford I . Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103(3):357-62. DOI: 10.1161/01.cir.103.3.357. View

15.

Swerdlow D, Preiss D, Kuchenbaecker K, Holmes M, Engmann J, Shah T . HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2014; 385(9965):351-61. PMC: 4322187. DOI: 10.1016/S0140-6736(14)61183-1. View

16.

Carter A, Gomes T, Camacho X, Juurlink D, Shah B, Mamdani M . Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346:f2610. PMC: 3662830. DOI: 10.1136/bmj.f2610. View

17.

Rajpathak S, Kumbhani D, Crandall J, Barzilai N, Alderman M, Ridker P . Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009; 32(10):1924-9. PMC: 2752935. DOI: 10.2337/dc09-0738. View

18.

Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716):735-42. DOI: 10.1016/S0140-6736(09)61965-6. View

19.

Laakso M, Fernandes Silva L . Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023; 14:1239335. PMC: 10546337. DOI: 10.3389/fendo.2023.1239335. View

20.

Ridker P, Pradhan A, MacFadyen J, Libby P, Glynn R . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380(9841):565-71. PMC: 3774022. DOI: 10.1016/S0140-6736(12)61190-8. View